Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR 0.0060
-0.0002 (-3.23%)
Apr 30, 2026, 5:35 PM CET
Fidia Revenue
Fidia had revenue of 13.59M EUR in the half year ending June 30, 2025, with 51.15% growth. This brings the company's revenue in the last twelve months to 21.13M, down -28.94% year-over-year. In the year 2024, Fidia had annual revenue of 17.53M, down -38.98%.
Revenue (ttm)
21.13M
Revenue Growth
-28.94%
P/S Ratio
0.00
Revenue / Employee
150.93K
Employees
140
Market Cap
99.90K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.53M | -11.20M | -38.98% |
| Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
| Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
| Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
| Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EuroGroup Laminations | 840.54M |
| Biesse | 662.48M |
| SIT S.p.A. | 319.10M |
| Tesmec | 257.61M |
| ILPRA | 86.63M |
| Clabo | 58.10M |
| Marzocchi Pompe | 37.47M |
| Valtecne | 37.24M |
Fidia News
- 10 hours ago - Market Today: Alphabet, Apple Lead as AI, Energy, FDA Move - GuruFocus
- 12 hours ago - AXSM Secures FDA Approval for Auvelity in Alzheimer's Agitation Treatment - GuruFocus
- 12 hours ago - AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant - GuruFocus
- 12 hours ago - Axsome Therapeutics (AXSM) Gains FDA Approval for Auvelity in Dementia Treatment - GuruFocus
- 12 hours ago - FDA Excludes Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List (LLY) - GuruFocus
- 13 hours ago - Axsome Therapeutics Receives FDA Approval for AXS-05 in Alzheimer's Treatment - GuruFocus
- 13 hours ago - Axsome Hits Record High On Alzheimer's Agitation Approval - Investor's Business Daily
- 13 hours ago - NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA Approval Insights - GuruFocus